Advances in huntington disease drug discovery: Novel approaches to model disease phenotypes

Journal of Biomolecular Screening

Volumn 19, Issue 2, 2014, Pages 191-204

  Bard, Jonathan ^a,b   Wall, Michael D ^c   Lazari, Ovadia ^c   Arjomand, Jamshid ^a,b   Munoz Sanjuan, Ignacio ^a,b  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^b BioFocus DPI Limited ^*

^c BioFocus DPI   (United Kingdom)

Author keywords

aggregation; huntingtin; Huntington disease; review; screening; stem cells; synaptic

Indexed keywords

HUNTINGTIN; PHOSPHODIESTERASE V INHIBITOR; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; Y 39983;

CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DISEASE MODEL; DRUG DEVELOPMENT; EMBRYONIC STEM CELL; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; REVIEW; RODENT MODEL;

AGGREGATION; HUNTINGTIN; HUNTINGTON DISEASE; REVIEW; SCREENING; STEM CELLS; SYNAPTIC;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; HUNTINGTON DISEASE; MICE; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; STEM CELLS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84892691641     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113510320     Document Type: Review

References (130)

1. The Huntington's Disease Collaborative Research Group. Cell. 1993 ; 72: 971-983
2. Biglan K. M., Ross C. A., Langbehn D. R., et al. Motor Abnormalities in Premanifest Persons with Huntington's Disease: The PREDICT-HD Study. Mov. Disord. 2009 ; 24: 1763-1772
3. Duff K., Paulsen J. S., Beglinger L. J., et al. Psychiatric Symptoms in Huntington's Disease before Diagnosis: The Predict-HD Study. Biol. Psychiatry. 2007 ; 62: 1341-1346 (Pubitemid 350180721)
4. Munoz-Sanjuan I., Bates G. P. The Importance of Integrating Basic and Clinical Research toward the Development of New Therapies for Huntington Disease. J. Clin. Invest. 2011 ; 121: 476-483
5. Duff K., Paulsen J. S., Beglinger L. J., et al. "Frontal" Behaviors before the Diagnosis of Huntington's Disease and Their Relationship to Markers of Disease Progression: Evidence of Early Lack of Awareness. J. Neuropsychiatry Clin. Neurosci. 2010 ; 22: 196-207
6. Zuccato C., Valenza M., Cattaneo E. Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease. Physiol. Rev. 2010 ; 90: 905-981
7. Cepeda C., Wu N., Andre V. M., et al. The Corticostriatal Pathway in Huntington's Disease. Prog. Neurobiol. 2007 ; 81: 253-271 (Pubitemid 46528639)
8. Gu X., Andre V. M., Cepeda C., et al. Pathological Cell-Cell Interactions Are Necessary for Striatal Pathogenesis in a Conditional Mouse Model of Huntington's Disease. Mol. Neurodegener. 2007 ; 2: 8
9. Heng M. Y., Detloff P. J., Albin R. L. Rodent Genetic Models of Huntington Disease. Neurobiol. Dis. 2008 ; 32: 1-9
10. von Horsten S., Schmitt I., Nguyen H. P., et al. Transgenic Rat Model of Huntington's Disease. Hum. Mol. Genet. 2003 ; 12: 617-624 (Pubitemid 36372488)
11. Strand A. D., Baquet Z. C., Aragaki A. K., et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration. J. Neurosci. 2007 ; 27: 11758-11768 (Pubitemid 350006916)
12. Slow E. J., van Raamsdonk J., Rogers D., et al. Selective Striatal Neuronal Loss in a YAC128 Mouse Model of Huntington Disease. Hum. Mol. Genet. 2003 ; 12: 1555-1567 (Pubitemid 36857303)
13. Gray M., Shirasaki D. I., Cepeda C., et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice. J. Neurosci. 2008 ; 28: 6182-6195
14. Brouillet E., Conde F., Beal M. F., et al. Replicating Huntington's Disease Phenotype in Experimental Animals. Prog. Neurobiol. 1999 ; 59: 427-468 (Pubitemid 29392967)
15. Cha J. H., Kosinski C. M., Kerner J. A., et al. Altered Brain Neurotransmitter Receptors in Transgenic Mice Expressing a Portion of an Abnormal Human Huntington Disease Gene. Proc. Natl. Acad. Sci. U. S. A. 1998 ; 95: 6480-6485 (Pubitemid 28249039)
16. Bjorkqvist M., Petersen A., Bacos K., et al. Progressive Alterations in the Hypothalamic-Pituitary-Adrenal Axis in the R6/2 Transgenic Mouse Model of Huntington's Disease. Hum. Mol. Genet. 2006 ; 15: 1713-1721 (Pubitemid 43904837)
17. Johnson M. A., Rajan V., Miller C. E., et al. Dopamine Release Is Severely Compromised in the R6/2 Mouse Model of Huntington's Disease. J. Neurochem. 2006 ; 97: 737-746
18. Luthi-Carter R., Strand A., Peters N. L., et al. Decreased Expression of Striatal Signaling Genes in a Mouse Model of Huntington's Disease. Hum. Mol. Genet. 2000 ; 9: 1259-1271 (Pubitemid 30312475)
19. Tsang T. M., Woodman B., McLoughlin G. A., et al. Metabolic Characterization of the R6/2 Transgenic Mouse Model of Huntington's Disease by High-Resolution MAS 1H NMR Spectroscopy. J. Proteome Res. 2006 ; 5: 483-492 (Pubitemid 43364087)
20. Tabrizi S. J., Workman J., Hart P. E., et al. Mitochondrial Dysfunction and Free Radical Damage in the Huntington R6/2 Transgenic Mouse. Ann. Neurol. 2000 ; 47: 80-86 (Pubitemid 30033653)
21. Jacobsen J. C., Bawden C. S., Rudiger S. R., et al. An Ovine Transgenic Huntington's Disease Model. Hum. Mol. Genet. 2010 ; 19: 1873-1882
22. Matsuyama N., Hadano S., Onoe K., et al. Identification and Characterization of the Miniature Pig Huntington's Disease Gene Homolog: Evidence for Conservation and Polymorphism in the CAG Triplet Repeat. Genomics. 2000 ; 69: 72-85
23. Uchida M., Shimatsu Y., Onoe K., et al. Production of Transgenic Miniature Pigs by Pronuclear Microinjection. Transgenic Res. 2001 ; 10: 577-582 (Pubitemid 34043182)
24. Yuhas D. Model Mammals: Sheep Are Helping Scientists Gain Ground against Huntington's Disease. Sci. Am. 2012 ; 307: 17
25. Morton A. J., Avanzo L. Executive Decision-Making in the Domestic Sheep. PLoS One. 2011 ; 6: e15752
26. Palfi S., Brouillet E., Jarraya B., et al. Expression of Mutated Huntingtin Fragment in the Putamen Is Sufficient to Produce Abnormal Movement in Non-Human Primates. Mol. Ther. 2007 ; 15: 1444-1451 (Pubitemid 47099301)
27. Burns L. H., Pakzaban P., Deacon T. W., et al. Selective Putaminal Excitotoxic Lesions in Non-Human Primates Model the Movement Disorder of Huntington Disease. Neuroscience. 1995 ; 64: 1007-1017
28. Yin D., Valles F. E., Fiandaca M. S., et al. Striatal Volume Differences between Non-Human and Human Primates. J. Neurosci. Methods. 2009 ; 176: 200-205
29. McBride J. L., Pitzer M. R., Boudreau R. L., et al. Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease. Mol. Ther. 2011 ; 19: 2152-2162
30. Davies S. W., Turmaine M., Cozens B. A., et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation. Cell. 1997 ; 90: 537-548 (Pubitemid 27347243)
31. DiFiglia M., Sapp E., Chase K. O., et al. Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain. Science. 1997 ; 277: 1990-1993 (Pubitemid 27449140)
32. Bates G. Huntingtin Aggregation and Toxicity in Huntington's Disease. Lancet. 2003 ; 361: 1642-1644 (Pubitemid 36579005)
33. Ross C. A. Huntington's Disease: New Paths to Pathogenesis. Cell. 2004 ; 118: 4-7 (Pubitemid 38902809)
34. Wanker E. E. Protein Aggregation and Pathogenesis of Huntington's Disease: Mechanisms and Correlations. Biol. Chem. 2000 ; 381: 937-942
35. Thakur A. K., Jayaraman M., Mishra R., et al. Polyglutamine Disruption of the Huntingtin Exon 1 N Terminus Triggers a Complex Aggregation Mechanism. Nat. Struct. Mol. Biol. 2009 ; 16: 380-389
36. Bhattacharyya A., Thakur A. K., Chellgren V. M., et al. Oligoproline Effects on Polyglutamine Conformation and Aggregation. J. Mol. Biol. 2006 ; 355: 524-535 (Pubitemid 41785754)
37. Wetzel R. Nucleation of Huntingtin Aggregation in Cells. Nat. Chem. Biol. 2006 ; 2: 297-298 (Pubitemid 43791505)
38. Sivanandam V. N., Jayaraman M., Hoop C. L., et al. The Aggregation-Enhancing Huntingtin N-terminus Is Helical in Amyloid Fibrils. J. Am. Chem. Soc. 2011 ; 133: 4558-4566
39. Jayaraman M., Kodali R., Sahoo B., et al. Slow Amyloid Nucleation via Alpha-Helix-Rich Oligomeric Intermediates in Short Polyglutamine-Containing Huntingtin Fragments. J. Mol. Biol. 2012 ; 415: 881-899
40. Mishra R., Jayaraman M., Roland B. P., et al. Inhibiting the Nucleation of Amyloid Structure in a Huntingtin Fragment by Targeting Alpha-Helix-Rich Oligomeric Intermediates. J. Mol. Biol. 2012 ; 415: 900-917
41. Arango M., Holbert S., Zala D., et al. CA150 Expression Delays Striatal Cell Death in Overexpression and Knock-in Conditions for Mutant Huntingtin Neurotoxicity. J. Neurosci. 2006 ; 26: 4649-4659 (Pubitemid 44315366)
42. Yang W., Dunlap J. R., Andrews R. B., et al. Aggregated Polyglutamine Peptides Delivered to Nuclei Are Toxic to Mammalian Cells. Hum. Mol. Genet. 2002 ; 11: 2905-2917
43. Gunawardena S., Her L. S., Brusch R. G., et al. Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic polyQ Proteins. Drosophila. Neuron. 2003 ; 40: 25-40 (Pubitemid 37222462)
44. Li H., Li S. H., Yu Z. X., et al. Huntingtin Aggregate-Associated Axonal Degeneration Is an Early Pathological Event in Huntington's Disease Mice. J. Neurosci. 2001 ; 21: 8473-8481 (Pubitemid 33051446)
45. Saudou F., Finkbeiner S., Devys D., et al. Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions. Cell. 1998 ; 95: 55-66
46. Hackam A. S., Singaraja R., Wellington C. L., et al. The Influence of Huntingtin Protein Size on Nuclear Localization and Cellular Toxicity. J. Cell Biol. 1998 ; 141: 1097-1105 (Pubitemid 28265605)
47. Kuemmerle S., Gutekunst C. A., Klein A. M., et al. Huntington Aggregates May Not Predict Neuronal Death in Huntington's Disease. Ann. Neurol. 1999 ; 46: 842-849
48. Slow E. J., Graham R. K., Osmand A. P., et al. Absence of Behavioral Abnormalities and Neurodegeneration In Vivo Despite Widespread Neuronal Huntingtin Inclusions. Proc. Natl. Acad. Sci. U. S. A. 2005 ; 102: 11402-11407 (Pubitemid 41153832)
49. Arrasate M., Mitra S., Schweitzer E. S., et al. Inclusion Body Formation Reduces Levels of Mutant Huntingtin and the Risk of Neuronal Death. Nature. 2004 ; 431: 805-810 (Pubitemid 39434070)
50. Horton T. M., Graham B. H., Corral-Debrinski M., et al. Marked Increase in Mitochondrial DNA Deletion Levels in the Cerebral Cortex of Huntington's Disease Patients. Neurology. 1995 ; 45: 1879-1883 (Pubitemid 27122962)
51. Arzberger T., Krampfl K., Leimgruber S., et al. Changes of NMDA Receptor Subunit (NR1, NR2B) and Glutamate Transporter (GLT1) mRNA Expression in Huntington's Disease - An In Situ Hybridization Study. J. Neuropathol. Exp. Neurol. 1997 ; 56: 440-454 (Pubitemid 27465027)
52. Augood S. J., Faull R. L., Love D. R., et al. Reduction in Enkephalin and Substance P Messenger RNA in the Striatum of Early Grade Huntington's Disease: A Detailed Cellular In Situ Hybridization Study. Neuroscience. 1996 ; 72: 1023-1036 (Pubitemid 26135583)
53. Augood S. J., Faull R. L., Emson P. C. Dopamine D1 and D2 Receptor Gene Expression in the Striatum in Huntington's Disease. Ann. Neurol. 1997 ; 42: 215-221 (Pubitemid 27340467)
54. Cha J. H., Frey A. S., Alsdorf S. A., et al. Altered Neurotransmitter Receptor Expression in Transgenic Mouse Models of Huntington's Disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999 ; 354: 981-989 (Pubitemid 29477958)
55. Norris P. J., Waldvogel H. J., Faull R. L., et al. Decreased Neuronal Nitric Oxide Synthase Messenger RNA and Somatostatin Messenger RNA in the Striatum of Huntington's Disease. Neuroscience. 1996 ; 72: 1037-1047 (Pubitemid 26135584)
56. Panov A. V., Gutekunst C. A., Leavitt B. R., et al. Early Mitochondrial Calcium Defects in Huntington's Disease Are a Direct Effect of Polyglutamines. Nat. Neurosci. 2002 ; 5: 731-736 (Pubitemid 34827590)
57. Cui L., Jeong H., Borovecki F., et al. Transcriptional Repression of PGC-1alpha by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. Cell. 2006 ; 127: 59-69 (Pubitemid 44466642)
58. Truant R., Atwal R. S., Desmond C., et al. Huntington's Disease: Revisiting the Aggregation Hypothesis in Polyglutamine Neurodegenerative Diseases. FEBS J. 2008 ; 275: 4252-4262
59. Davies J. E., Sarkar S., Rubinsztein D. C. The Ubiquitin Proteasome System in Huntington's Disease and the Spinocerebellar Ataxias 2007. BMC Biochem 8.: S2
60. Martinez-Vicente M., Talloczy Z., Wong E., et al. Cargo Recognition Failure Is Responsible for Inefficient Autophagy in Huntington's Disease. Nat. Neurosci. 2010 ; 13: 567-576
61. Krainc D. Clearance of Mutant Proteins as a Therapeutic Target in Neurodegenerative Diseases. Arch. Neurol. 2010 ; 67: 388-392
62. Wong E., Cuervo A. M. Autophagy Gone Awry in Neurodegenerative Diseases. Nat. Neurosci. 2010 ; 13: 805-811
63. Williams A., Sarkar S., Cuddon P., et al. Novel Targets for Huntington's Disease in an mTOR-Independent Autophagy Pathway. Nat. Chem. Biol. 2008 ; 4: 295-305 (Pubitemid 351550888)
64. Titus S. A., Southall N., Marugan J., et al. High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model. Curr. Chem. Genomics. 2012 ; 6: 79-86
65. Fuentealba R. A., Marasa J., Diamond M. I., et al. An aggregation Sensing Reporter Identifies Leflunomide and Teriflunomide as Polyglutamine Aggregate Inhibitors. Hum. Mol. Genet. 2012 ; 21: 664-680
66. Nollen E. A., Garcia S. M., van Haaften G., et al. Genome-wide RNA Interference Screen Identifies Previously Undescribed Regulators of Polyglutamine Aggregation. Proc. Natl. Acad. Sci. U. S. A. 2004 ; 101: 6403-6408 (Pubitemid 38585986)
67. Teuling E., Bourgonje A., Veenje S., et al. Modifiers of Mutant Huntingtin Aggregation: Functional Conservation of C. elegans-Modifiers of Polyglutamine Aggregation. PLoS Curr. 2011 ; 3 :
68. Doumanis J., Wada K., Kino Y., et al. RNAi Screening in Drosophila Cells Identifies New Modifiers of Mutant Huntingtin Aggregation. PLoS One. 2009 ; 4: e7275
69. Lazzeroni G., Benicchi T., Heitz F., et al. A Phenotypic Screening Assay for Modulators of Huntingtin-Induced Transcriptional Dysregulation. J. Biomol. Screen. 2013 ; 18: 984-996
70. Coufal M., Maxwell M. M., Russel D. E., et al. Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments. J. Biomol. Screen. 2007 ; 12: 351-360 (Pubitemid 46514677)
71. Baldo B., Weiss A., Parker C. N., et al. A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client Protein. J. Biol. Chem. 2012 ; 287: 1406-1414
72. Weiss A., Trager U., Wild E. J., et al. Mutant Huntingtin Fragmentation in Immune Cells Tracks Huntington's Disease Progression. J. Clin. Invest. 2012 ; 122: 3731-3736
73. Myers R. H. Huntington's Disease Genetics. NeuroRx. 2004 ; 1: 255-262 (Pubitemid 46589355)
74. Zhang X., Smith D. L., Meriin A. B., et al. A Potent Small Molecule Inhibits Polyglutamine Aggregation in Huntington's Disease Neurons and Suppresses Neurodegeneration In Vivo. Proc. Natl. Acad. Sci. U. S. A. 2005 ; 102: 892-897 (Pubitemid 40282761)
75. Chopra V., Fox J. H., Lieberman G., et al. A Small-Molecule Therapeutic Lead for Huntington's Disease: Preclinical Pharmacology and Efficacy of C2-8 in the R6/2 Transgenic Mouse. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 16685-16689 (Pubitemid 350211077)
76. Choi S. H., Quinti L., Kazantsev A. G., et al. 3-(N-arylsulfamoyl) benzamides, Inhibitors of Human Sirtuin Type 2 (SIRT2). Bioorg. Med. Chem. Lett. 2012 ; 22: 2789-2793
77. Wu J., Shih H. P., Vigont V., et al. Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment. Chem. Biol. 2011 ; 18: 777-793
78. Apostol B. L., Illes K., Pallos J., et al. Mutant Huntingtin Alters MAPK Signaling Pathways in PC12 and Striatal Cells: ERK1/2 Protects against Mutant Huntingtin-Associated Toxicity. Hum. Mol. Genet. 2006 ; 15: 273-285 (Pubitemid 43125981)
79. Deyts C., Galan-Rodriguez B., Martin E., et al. Dopamine D2 Receptor Stimulation Potentiates PolyQ-Huntingtin-Induced Mouse Striatal Neuron Dysfunctions via Rho/ROCK-II Activation. PLoS One. 2009 ; 4: e8287
80. Wishart T. M., Rooney T. M., Lamont D. J., et al. Combining Comparative Proteomics and Molecular Genetics Uncovers Regulators of Synaptic and Axonal Stability and Degeneration In Vivo. PLoS Genet. 2012 ; 8: e1002936
81. Miller J. P., Yates B. E., Al-Ramahi I., et al. A Genome-Scale RNA-Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington's Disease. PLoS Genet. 2012 ; 8: e1003042
82. Schulte J., Sepp K. J., Wu C., et al. High-Content Chemical and RNAi Screens for Suppressors of Neurotoxicity in a Huntington's Disease Model. PLoS One. 2011 ; 6: e23841
83. Lejeune F. X., Mesrob L., Parmentier F., et al. Large-Scale Functional RNAi Screen in C. elegans Identifies Genes That Regulate the Dysfunction of Mutant Polyglutamine Neurons. BMC Genomics. 2012 ; 13: 91
84. Okamoto Y., Nagai Y., Fujikake N., et al. Surface Plasmon Resonance Characterization of Specific Binding of Polyglutamine Aggregation Inhibitors to the Expanded Polyglutamine Stretch. Biochem. Biophys. Res. Commun. 2009 ; 378: 634-639
85. Lanning J. D., Hawk A. J., Derryberry J., et al. Chaperone-like N-methyl Peptide Inhibitors of Polyglutamine Aggregation. Biochemistry. 2010 ; 49: 7108-7118
86. Nagai Y., Tucker T., Ren H., et al. Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening. J. Biol. Chem. 2000 ; 275: 10437-10442 (Pubitemid 30202104)
87. Klein F. A., Pastore A., Masino L., et al. Pathogenic and Non-Pathogenic Polyglutamine Tracts Have Similar Structural Properties: Towards a Length-Dependent Toxicity Gradient. J. Mol. Biol. 2007 ; 371: 235-244 (Pubitemid 47044840)
88. Vonsattel J. P., Myers R. H., Stevens T. J., et al. Neuropathological Classification of Huntington's Disease. J. Neuropathol. Exp. Neurol. 1985 ; 44: 559-577 (Pubitemid 16196286)
89. Sapp E., Schwarz C., Chase K., et al. Huntingtin Localization in Brains of Normal and Huntington's Disease Patients. Ann. Neurol. 1997 ; 42: 604-612 (Pubitemid 27439023)
90. Kaltenbach L. S., Bolton M. M., Shah B., et al. Composite Primary Neuronal High-Content Screening Assay for Huntington's Disease Incorporating Non-Cell-Autonomous Interactions. J. Biomol. Screen. 2010 ; 15: 806-819
91. Sharma P., Ando D. M., Daub A., et al. High-Throughput Screening in Primary Neurons. Methods Enzymol. 2012 ; 506: 331-360
92. Reinhart P. H., Kaltenbach L. S., Essrich C., et al. Identification of Anti-Inflammatory Targets for Huntington's Disease Using A Brain Slice-Based Screening Assay. Neurobiol. Dis. 2011 ; 43: 248-256
93. Heikkinen T., Lehtimaki K., Vartiainen N., et al. Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-in Mouse Model of Huntington's Disease. PLoS One. 2012 ; 7: e50717
94. Raymond L. A., Andre V. M., Cepeda C., et al. Pathophysiology of Huntington's Disease: Time-Dependent Alterations in Synaptic and Receptor Function. Neuroscience. 2011 ; 198: 252-273
95. Cummings D. M., Cepeda C., Levine M. S. Alterations in Striatal Synaptic Transmission Are Consistent across Genetic Mouse Models of Huntington's Disease. ASN Neuro. 2010 ; 2: e00036
96. Johnstone A. F., Gross G. W., Weiss D. G., et al. Microelectrode Arrays: A Physiologically Based Neurotoxicity Testing Platform for the 21st Century. Neurotoxicology. 2010 ; 31: 331-350
97. Kleiman R. J., Schmidt C., Harms J., et al. cGMP Phosphodiesterase inhibitors rescue deficits in synaptic plasticity and medium spiny neuron excitability in transgenic Huntingtons Disease mouse models. 2011 ;:
98. Conforti P., Camnasio S., Mutti C., et al. Lack of Huntingtin Promotes Neural Stem Cells Differentiation into Glial Cells While Neurons Expressing Huntingtin with Expanded Polyglutamine Tracts Undergo Cell Death. Neurobiol. Dis. 2013 ; 50: 160-170
99. Feyeux M., Bourgois-Rocha F., Redfern A., et al. Early Transcriptional Changes Linked to Naturally Occurring Huntington's Disease Mutations in Neural Derivatives of Human Embryonic Stem Cells. Hum. Mol. Genet. 2012 ; 21: 3883-3895
100. Jacobsen J. C., Gregory G. C., Woda J. M., et al. HD CAG-Correlated Gene Expression Changes Support a Simple Dominant Gain of Function. Hum. Mol. Genet. 2011 ; 20: 2846-2860
101. Lo Sardo V., Zuccato C., Gaudenzi G., et al. An Evolutionary Recent Neuroepithelial Cell Adhesion Function of Huntingtin Implicates ADAM10-Ncadherin. Nat. Neurosci. 2012 ; 15: 713-721
102. Nguyen G. D., Gokhan S., Molero A. E., et al. Selective Roles of Normal and Mutant Huntingtin in Neural Induction and Early Neurogenesis. PLoS One. 2013 ; 8: e64368
103. Ritch J. J., Valencia A., Alexander J., et al. Multiple Phenotypes in Huntington Disease Mouse Neural Stem Cells. Mol. Cell Neurosci. 2012 ; 50: 70-81
104. Mateizel I., De Temmerman N., Ullmann U., et al. Derivation of Human Embryonic Stem Cell Lines from Embryos Obtained after IVF and after PGD for Monogenic Disorders. Hum. Reprod. 2006 ; 21: 503-511 (Pubitemid 43159929)
105. Niclis J., Trounson A. O., Dottori M., et al. Human Embryonic Stem Cell Models of Huntington Disease. Reprod. Biomed. Online. 2009 ; 19: 106-113
106. Verlinsky Y., Tur-Kaspa I., Cieslak J., et al. Preimplantation Testing for Chromosomal Disorders Improves Reproductive Outcome of Poor-Prognosis Patients. Reprod. Biomed. Online. 2005 ; 11: 219-225 (Pubitemid 41086948)
107. Lu B., Palacino J. A Novel Human Embryonic Stem Cell-Derived Huntington's Disease Neuronal Model Exhibits Mutant Huntingtin (mHTT) Aggregates and Soluble mHTT-Dependent Neurodegeneration. FASEB J. 2013 ; 27: 1820-1829
108. Subramaniam S., Sixt K. M., Barrow R., et al. Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity. Science. 2009 ; 324: 1327-1330
109. Bilican B., Serio A., Barmada S. J., et al. Mutant Induced Pluripotent Stem Cell Lines Recapitulate Aspects of TDP-43 Proteinopathies and Reveal Cell-Specific Vulnerability. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 5803-5808
110. Egawa N., Kitaoka S., Tsukita K., et al. Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells. Sci. Transl. Med. 2012 ; 4 :
111. Wray S., Self M., Lewis P. A., et al. Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS One. 2012 ; 7: e43099
112. Park I. H., Arora N., Huo H., et al. Disease-Specific Induced Pluripotent Stem Cells. Cell. 2008 ; 134: 877-886
113. Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated Phenotypes. Cell Stem Cell. 2012 ; 11: 264-278
114. Camnasio S., Delli Carri A., Lombardo A., et al. The First Reported Generation of Several Induced Pluripotent Stem Cell Lines from Homozygous and Heterozygous Huntington's Disease Patients Demonstrates Mutation Related Enhanced Lysosomal Activity. Neurobiol. Dis. 2012 ; 46: 41-51
115. An M. C., Zhang N., Scott G., et al. Genetic Correction of Huntington's Disease Phenotypes in Induced Pluripotent Stem Cells. Cell Stem Cell. 2012 ; 11: 253-263
116. Chae J. I., Kim D. W., Lee N., et al. Quantitative Proteomic Analysis of Induced Pluripotent Stem Cells Derived from a Human Huntington's Disease Patient. Biochem. J. 2012 ; 446: 359-371
117. Jeon I., Lee N., Li J. Y., et al. Neuronal Properties, In Vivo Effects, and Pathology of a Huntington's Disease Patient-Derived Induced Pluripotent Stem Cells. Stem Cells. 2012 ; 30: 2054-2062
118. Zhang N., An M. C., Montoro D., et al. Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells. PLoS Curr. 2010 ; 2 :
119. Aubry L., Bugi A., Lefort N., et al. Striatal Progenitors Derived from Human ES Cells Mature into DARPP32 Neurons In Vitro and in Quinolinic Acid-Lesioned Rats. Proc. Natl. Acad. Sci. U. S. A. 2008 ; 105: 16707-16712
120. Delli Carri A., Onorati M., Castiglioni V., et al. Human Pluripotent Stem Cell Differentiation into Authentic Striatal Projection Neurons. Stem Cell Rev. 2013 ; 9: 461-474
121. Juopperi T. A., Kim W. R., Chiang C. H., et al. Astrocytes Generated from Patient Induced Pluripotent Stem Cells Recapitulate Features of Huntington's Disease Patient Cells. Mol. Brain. 2012 ; 5: 17
122. Zhang Y., Schulz V. P., Reed B. D., et al. Functional Genomic Screen of Human Stem Cell Differentiation Reveals Pathways Involved in Neurodevelopment and Neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2013 ; 110: 12361-12366
123. Liu Y., Lacson R., Cassaday J., et al. Identification of Small-Molecule Modulators of Mouse SVZ Progenitor Cell Proliferation and Differentiation through High-Throughput Screening. J. Biomol. Screen. 2009 ; 14: 319-329
124. Desbordes S. C., Studer L. Adapting Human Pluripotent Stem Cells to High-Throughput and High-Content Screening. Nat. Protoc. 2013 ; 8: 111-130
125. Sarkar S., Perlstein E. O., Imarisio S., et al. Small Molecules Enhance Autophagy and Reduce Toxicity in Huntington's Disease Models. Nat. Chem. Biol. 2007 ; 3: 331-338 (Pubitemid 46789270)
126. Zhang L., Yu J., Pan H., et al. Small Molecule Regulators of Autophagy Identified by an Image-Based High-Throughput Screen. Proc. Natl. Acad. Sci. U. S. A. 2007 ; 104: 19023-19028
127. Wang W., Duan W., Igarashi S., et al. Compounds Blocking Mutant Huntingtin Toxicity Identified Using a Huntington's Disease Neuronal Cell Model. Neurobiol. Dis. 2005 ; 20: 500-508 (Pubitemid 41476276)
128. Miller J. P., Holcomb J., Al-Ramahi I., et al. Matrix Metalloproteinases Are Modifiers of Huntingtin Proteolysis and Toxicity in Huntington's Disease. Neuron. 2010 ; 67: 199-212
129. Liu C. R., Chang C. R., Chern Y., et al. Spt4 Is Selectively Required for Transcription of Extended Trinucleotide Repeats. Cell. 2012 ; 148: 690-701
130. Brignull H. R., Morley J. F., Garcia S. M., et al. Modeling Polyglutamine Pathogenesis. C. elegans. Methods Enzymol. 2006 ; 412: 256-282